With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
Limited time offer $125 $99 for 1 year
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
The quiet, conservative Ahmedabad-based drug maker is ready to pledge family silver to acquire a rival many times its size. The question is whether it can survive its ambition.